Treating type 1 and type 2 diabetes with investigational ultra rapid acting mealtime insulin Afrezza (insulin human [rDNA origin]) Inhalation Powder does not result in excess cardiovascular events according to two new studies being presented at the American Diabetes Association’s 71stScientific Sessions in San Diego. The findings of the two separate studies demonstrated that inhaled Afrezza did not produce clinically significant effects on heart rate, PR and QRS interval duration, or cardiac morphology.Afrezza is a novel, ultra rapid-acting mealtime insulin therapy in late stage clinical investigation for the treatment of adult patients with type 1 and type 2 diabetes for the control of hyperglycemia. Two phase 3, multicenter clinical trials are currently underway to evaluate the efficacy and safety of Afrezza using MannKind Corporation’s next generation inhalation device.
Results of a new patient-reported outcomes (PRO) study show that patients with type 1 diabetes who received the investigational ultra rapid acting mealtime insulin, Afrezza (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, came to view insulin therapy more positively during the course of a 16-week study compared with patients using standard therapy insulin lispro, a rapid acting insulin, combined with basal insulin.
